Company intelligence / Profile preview

Teracero Pharma

Ownership: Private
Development stage: Commercial

Overview

Teracero Pharma received authorization for its NADAL COVID-19 serology rapid test, which demonstrated extremely high specificity (>98%) across nine independent studies with over 1,250 clinical samples analyzed[2].

Therapeutic areas: Infectious Diseases
Modalities: Rapid diagnostic tests (serology)
Industry: Protein Biomarker Diagnostics

Drug pipeline

1 asset

NADAL COVID-19 IgG/IgM Test

Commercial

Indications: COVID-19 serology testing

Partnerships

nal von minden GmbH (manufacturer/distributor of NADAL tests)[2]

Beyond the preview

Go deeper on Teracero Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Teracero Pharma.

Explore the full profile